LivaNova PLC (LIVN)
Stock Price Chart
Key Info
| Market Cap | 2.27B |
| Revenue (ttm) | 980.80M |
| Net Income (ttm) | -161.52M |
| Shares Out | 48.67M |
| EPS (ttm) | -3.33 |
| PE Ratio | n/a |
| Forward PE | 46.73 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 6, 2020 |
| Last Price | $46.73 |
| Previous Close | $47.38 |
| Change ($) | -0.65 |
| Change (%) | -1.37% |
| Day's Open | 47.14 |
| Day's Range | 46.62 - 47.99 |
| Day's Volume | 61,036 |
| 52-Week Range | 33.40 - 87.45 |
More Stats
| Market Cap | 2.27B |
| Enterprise Value | 2.73B |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 48.67M |
| Float | 48.43M |
| EPS (basic) | -3.33 |
| EPS (diluted) | -3.33 |
| FCF / Share | -4.75 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 3.16M |
| Short Ratio | 4.38 |
| Short % of Float | 6.80% |
| Beta | 0.84 |
| PE Ratio | n/a |
| Forward PE | 46.73 |
| P/FCF Ratio | n/a |
| PS Ratio | 2.32 |
| PB Ratio | 1.81 |
| Revenue | 980.80M |
| Operating Income | -132.84M |
| Net Income | -161.52M |
| Free Cash Flow | -230.64M |
| Net Cash | -456.48M |
| Net Cash / Share | -9.38 |
| Gross Margin | 74.59% |
| Operating Margin | -13.54% |
| Profit Margin | -16.50% |
| FCF Margin | -23.51% |
| ROA | -1.08% |
| ROE | -11.41% |
| ROIC | -15.60% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,084 | 1,107 | 1,012 | 965 | 292 | 282 | 254 | 681 |
| Revenue Growth | -2.06% | 9.35% | 4.91% | 230.93% | 3.38% | 10.89% | -62.63% | - |
| Gross Profit | 745 | 734 | 652 | 559 | 264 | 255 | 232 | 371 |
| Operating Income | -169 | -237 | 127 | 33.45 | 88.65 | 80.01 | 78.35 | 33.22 |
| Net Income | -155 | -189 | -25.09 | -62.79 | 57.85 | 54.89 | 46.36 | 18.24 |
| Shares Outstanding | 48.35 | 48.50 | 48.16 | 48.86 | 26.39 | 27.14 | 27.60 | - |
| Earnings Per Share | -3.21 | -3.91 | -0.52 | -1.28 | 2.17 | 2.00 | 1.66 | 0.04 |
| EPS Growth | - | - | - | - | 8.5% | 20.48% | 4511.11% | - |
| Operating Cash Flow | -91.14 | 120 | 91.34 | 90.15 | 79.68 | 54.20 | 79.05 | 71.59 |
| Capital Expenditures | -24.69 | -37.19 | -32.93 | -38.36 | -6.69 | -15.22 | -9.71 | -19.97 |
| Free Cash Flow | -116 | 83.30 | 58.41 | 51.79 | 72.99 | 38.97 | 69.35 | 51.61 |
| Cash & Equivalents | 61.14 | 47.20 | 93.62 | 39.79 | 151 | 128 | 0.00 | 0.00 |
| Total Debt | 384 | 168 | 146 | 123 | - | - | - | - |
| Net Cash / Debt | -323 | -121 | -52.38 | -83.08 | 151 | 128 | 0.00 | 0.00 |
| Assets | 2,412 | 2,550 | 2,504 | 2,343 | 316 | 294 | - | - |
| Liabilities | 1,028 | 1,046 | 689 | 636 | 39.37 | 35.09 | - | - |
| Book Value | 1,384 | 1,504 | 1,815 | 1,707 | 277 | 259 | - | - |
Company Profile
Company Details
| Full Name | LivaNova PLC |
| Country | United Kingdom |
| Employees | 4,000 |
| CEO | Damien McDonald |
Stock Information
| Ticker Symbol | LIVN |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: LIVN |
| IPO Date | February 10, 1993 |
Description
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.